Fulgent Genetics (FLGT) Receivables - Net (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Receivables - Net data on file, last reported at $69.3 million in Q1 2026.

• Quarterly Receivables - Net fell 3.08% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (down 3.08% YoY) and the FY2025 annual result came in at $84.8 million, up 22.81% from the prior year.
• Receivables - Net retreated to $69.3 million in Q1 2026 per FLGT's latest filing, from $84.8 million in the prior quarter.
• The five-year high for Receivables - Net was $160.3 million in Q1 2022, with the low at $13000.0 in Q3 2023.
• Average Receivables - Net over 5 years is $69.9 million, with a median of $69.0 million recorded in 2024.
• Year-over-year, Receivables - Net slumped 99.99% in 2023 and jumped 440784.62% in 2024.
• Fulgent Genetics' Receivables - Net stood at $52.7 million in 2022, then dropped by 3.07% to $51.1 million in 2023, then jumped by 34.99% to $69.0 million in 2024, then gained by 22.81% to $84.8 million in 2025, then slipped by 18.27% to $69.3 million in 2026.
• Business Quant data shows FLGT's Receivables - Net at $69.3 million in Q1 2026, $84.8 million in Q4 2025, and $71.2 million in Q3 2025.